SUZHOU, China, June 17, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the clinical results of CT103A, the potential best-in-class therapy of...
from PR Newswire: https://www.prnewswire.com:443/news-releases/results-of-fully-human-bcma-car-t-for-the-treatment-of-relapsedrefractory-multiple-myeloma-co-developed-by-innovent-and-iaso-bio-presented-at-2019-asco-and-eha-annual-meetings-300869542.html
No comments:
Post a Comment